Prof. Jiyan Liu 刘继彦
Chief Physician, Professor
Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology focusing on chemotherapy, biological immunotherapy, and molecular targeted therapy for colorectal, gastric, renal, bladder, prostate, ovarian, uterine cancers, malignant melanoma, and testicular tumors.
Dr. Liu holds an MD and PhD. After graduating in 1997, Dr. Liu worked at West China Hospital. Dr. Liu completed a postdoctoral fellowship at Sun Yat-sen University Cancer Center in 2005 and visited M.D. Anderson Cancer Center from 2012 to 2013. Research focuses on targeted drug application, resistance mechanisms, and immunotherapy. Dr. Liu has published over 50 articles.
Professional roles
- Member, Tumor Molecular Targeted Therapy Professional Committee, Chinese Society of Medical Engineering
- Standing Committee Member, Tumor Targeted Therapy Professional Committee, Sichuan Anti-Cancer Association
- Member, Clinical Oncology Collaboration Professional Committee, China Anti-Cancer Association
- Invited Editorial Board Member, Military Medical Journal
Name order: in Chinese the family name comes first (Liu Jiyan). Papers usually list the name as Jiyan Liu or Liu J.
Selected publications
167 papers on PubMed matched by name and affiliation; 46 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Ther, 2026 (senior author): DC vaccine loaded with Bacteroides fragilis elicits functional cross-reactivity and enhances anti-PD-1 immunotherapy. PubMed 42596550
- Future Oncol, 2026 (senior author): MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis. PubMed 42757773
- J Transl Med, 2026 (senior author): SIRT3 regulates mitochondrial metabolism through deacetylation of SLC25A6 to impact gastric cancer progression and drug resistance. PubMed 42260555
- Int J Cancer, 2026 (senior author): Anti-epidermal growth factor receptor monoclonal antibody combined with chemotherapy in penile cancer: A prospective, multicenter, phase 1 study. PubMed 41230859
- NPJ Digit Med, 2026 (senior author): Distinction between primary and metastatic mucinous ovarian carcinoma from histopathology images using deep learning. PubMed 41735519
- Front Oncol, 2026 (senior author): Histopathology images-based deep learning prediction of prognosis in primary mucinous ovarian carcinoma. PubMed 41727660
- Cancer Cell Int, 2025 (senior author): CD44 on cancer stem cell is a potential immunological and prognostic pan-cancer biomarker. PubMed 40200220
- BMC Cancer, 2025 (senior author): Causal relationship between immune cell signatures and colorectal cancer: a bi-directional, two-sample mendelian randomization study. PubMed 40033246
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion